A Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma

NCT03096912 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER_GOV

Sponsor class

Conditions

Liposarcomas, Dedifferentiated
Liposarcoma - Well Differentiated
Liposarcoma; Mixed Type
Soft-Tissue Sarcoma

Interventions

DRUG: Ribociclib

Sponsor

Assaf-Harofeh Medical Center